THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Sunday, October 18, 2020
metaMe Health Collaborates with Indegene to launch a breakthrough Prescription Digital Therapeutics, Regulora, to help patients dealing with abdominal pain due to IBS.
Fremont, CA: Irritable bowel syndrome (IBS) is a chronic illness that affects 10-15 percent of individuals in the United States. Abdominal pain is the primary symptom, which may be accompanied by diarrhea (IBS-D), constipation (IBS-C), or a combination of the two (IBS-M). IBS has a significant negative impact on one's quality of life. IBS sufferers believe they would give up 25 percent of their remaining life to live symptom-free, according to a survey of over 2,000 patients. MetaMe Health, Inc. (metaMe), a Prescription Digital Therapeutics (PDT) firm and developer of Regulora, have formed a partnership to bring Regulora to market for the treatment of abdominal pain caused by Irritable Bowel Syndrome (IBS).
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Indegene will collaborate with metaMe Health over a multi-year period to educate healthcare providers, patients, and payers about the benefits of this breakthrough treatment using its flexible and capital-efficient commercial strategy. Indegene delivers extensive healthcare expertise and powerful omnichannel capabilities powered by artificial intelligence and machine learning to help metaMe Health launch Regulora. Regulora reaches the correct patients because to Indegenes' unique Co-Commercialization model, which allows metaMe to focus on its purpose of producing breakthrough Prescription Digital Therapeutics.
Check Out This: Food Business Review
“metaMe Healths Regulora is the first FDA-authorized PDT specifically for abdominal pain associated with IBS in adults. It provides self-administered Gut-Directed Hypnotherapy (GDH) through a convenient iOS and Android app that can be used at home along with other IBS treatments. Until now, the availability of GDH has been limited, as it has been provided in person by specialized therapists. Regulora now makes this treatment accessible to any adult with IBS through their doctor or GI specialist, and also makes it far more convenient because no therapist visits are needed to receive Regulora,” states Dr. Olafur Palsson, Professor of Medicine in the Division of Gastroenterology and Hepatology at the University of North Carolina.
Tim Rudolphi, CEO at metaMe Health, comments, “We are excited to introduce Regulora as the first FDA-authorized treatment of its kind for IBS in adults. Indegene’s end-to-end commercialization process gives us confidence that this therapy will reach patients and improve their quality of life. It is great to have a partner like Indegene we can trust to manage the complexities of the process of taking our product to market.”
More in News